Drug intelligence / Profile preview

teropavimab + zinlirvimab

Development stage: Unknown
Lead developer: Gilead Sciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Teropavimab (3BNC117-LS-J) and zinlirvimab (10-1074-LS-J) are a combination of two long-acting broadly neutralizing antibodies (bNAbs) being developed for HIV treatment. 3BNC117-LS-J targets the CD4 binding site on HIV envelope gp160, while 10-1074-LS-J targets a different site on the HIV envelope. This combination is being evaluated for its ability to maintain viral suppression during analytical treatment interruption (ATI) of antiretroviral therapy in people living with HIV. Clinical trials are investigating whether this combination can prevent viral rebound after discontinuation of antiretroviral therapy.

Other names: 3BNC117-LS-J and 10-1074-LS-J combination

Targets

V3 glycan patch (HIV-1 gp120 V3 glycan patch)

Beyond the preview

Go deeper on teropavimab + zinlirvimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on teropavimab + zinlirvimab.

Explore the full profile